GangaGen is a biotech company that’s working on bacteriophages, which are viruses that infect and destroy bacteria. The company raised $1.8 million to develop treatments for antibiotic-resistant bacterial infections like pneumonia and MRSA, a skin infection that plagues hospitals.

This is the San Francisco, Calif. company’s first funding round. ATEL Ventures made the investment.

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.